A System for Rapidly Yet Rigorously Evaluating the Quality of Randomized Controlled Trials

被引:1
作者
Smith, Eric G. [1 ,2 ,3 ,4 ]
Grigorian, Hannah L. [1 ]
机构
[1] VA Bedford Healthcare Syst, Bedford, MA USA
[2] UMassChan Med Sch, Dept Psychiat, Worcester, MA, Brazil
[3] UMassChan Med Sch, Dept Populat & Quantitat Hlth Sci, Worcester, MA, Brazil
[4] VA Bedford Healthcare Syst, Ctr Healthcare Org & Implementat Res, 200 Springs Rd, Bedford, MA 01730 USA
关键词
tutorial; BIS FOES; randomized clinical trials; evaluation of randomized trials; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; MISSING DATA; DEPRESSION; PREVENTION; PSYCHOTHERAPY; THERAPY; INTERVENTION; ESCITALOPRAM; IMIPRAMINE;
D O I
10.1097/JCP.0000000000001724
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This tutorial describes a system for rapidly yet rigorously assessing the quality of randomized controlled trials (RCTs). The system has 7 criteria, represented by the acronym "BIS FOES." The BIS FOES system directs readers to assess RCTs based on the following 7 criteria: the RCT's use (or not) of effective (1) Blinding; the RCT's use (or not) of (2) Intent-to-Treat Analysis; the RCT's (3) Size and other information reflecting the effectiveness of randomization; the amount of sample lost during (4) Follow-up; the (5) Outcomes examined by the RCT (specifically, the outcome measures used by the RCT), the (6) Efects reported (ie, the statistical and clinical significance of the RCT's primary, secondary, and safety findings), and any (7) Special Considerations (ie, additional strengths, limitations, or notable features of the RCT). The first 6 criteria are of basic importance to the assessment of every RCT, whereas the Special Considerations criteria allows the system to be expanded to include virtually any other important aspect of the RCT. This tutorial explains the importance of these criteria and how to assess them. This tutorial also describes how many BIS FOES criteria can be initially assessed from the RCT Abstract while also directing readers to specific locations in the RCT article where additional important information can be found. We hope that the BIS FOES system will help healthcare trainees, but also potentially clinicians, researchers, and the general public, rapidly and thoroughly assess RCTs.
引用
收藏
页码:306 / 312
页数:7
相关论文
共 76 条
  • [1] Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study
    Abraha, Iosief
    Cherubini, Antonio
    Cozzolino, Francesco
    De Florio, Rita
    Luchetta, Maria Laura
    Rimland, Joseph M.
    Folletti, Ilenia
    Marchesi, Mauro
    Germani, Antonella
    Orso, Massimiliano
    Eusebi, Paolo
    Montedori, Alessandro
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
  • [2] Understanding randomised controlled trials
    Akobeng, AK
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2005, 90 (08) : 840 - 844
  • [3] Intent-to-Treat (ITT) vs Completer or Per-Protocol Analysis in Randomized Controlled Trials
    Andrade, Chittaranjan
    [J]. INDIAN JOURNAL OF PSYCHOLOGICAL MEDICINE, 2022, 44 (04) : 416 - 418
  • [4] Effect of a Digital Intervention on Depressive Symptoms in Patients With Comorbid Hypertension or Diabetes in Brazil and Peru: Two Randomized Clinical Trials
    Araya, Ricardo
    Menezes, Paulo Rossi
    Claro, Heloisa Garcia
    Brandt, Lena R.
    Daley, Kate L.
    Quayle, Julieta
    Diez-Canseco, Francisco
    Peters, Tim J.
    Cruz, Daniela Vera
    Toyama, Mauricio
    Aschar, Suzana
    Hidalgo-Padilla, Liliana
    Martins, Hellen
    Cavero, Victoria
    Rocha, Thais
    Scotton, George
    de Almeida Lopes, Ivan F.
    Begale, Mark
    Mohr, David C.
    Jaime Miranda, J.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (18): : 1852 - 1862
  • [5] Influence of pilot and small trials in meta-analyses of behavioral interventions: a meta-epidemiological study
    Beets, Michael W.
    Weaver, R. Glenn
    Ioannidis, John P. A.
    Pfledderer, Christopher D.
    Jones, Alexis
    von Klinggraeff, Lauren
    Armstrong, Bridget
    [J]. SYSTEMATIC REVIEWS, 2023, 12 (01)
  • [6] Controlling the false discovery rate in behavior genetics research
    Benjamini, Y
    Drai, D
    Elmer, G
    Kafkafi, N
    Golani, I
    [J]. BEHAVIOURAL BRAIN RESEARCH, 2001, 125 (1-2) : 279 - 284
  • [7] A roadmap to using randomization in clinical trials
    Berger, Vance W.
    Bour, Louis Joseph
    Carter, Kerstine
    Chipman, Jonathan J.
    Everett, Colin C.
    Heussen, Nicole
    Hewitt, Catherine
    Hilgers, Ralf-Dieter
    Luo, Yuqun Abigail
    Renteria, Jone
    Ryeznik, Yevgen
    Sverdlov, Oleksandr
    Uschner, Diane
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2021, 21 (01)
  • [8] Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder A Randomized Clinical Trial
    Bogenschutz, Michael P.
    Ross, Stephen
    Bhatt, Snehal
    Baron, Tara
    Forcehimes, Alyssa A.
    Laska, Eugene
    Mennenga, Sarah E.
    O'Donnell, Kelley
    Owens, Lindsey T.
    Podrebarac, Samantha
    Rotrosen, John
    Tonigan, J. Scott
    Worth, Lindsay
    [J]. JAMA PSYCHIATRY, 2022, 79 (10) : 953 - 962
  • [9] Trial of Psilocybin versus Escitalopram for Depression
    Carhart-Harris, Robin
    Giribaldi, Bruna
    Watts, Rosalind
    Baker-Jones, Michelle
    Murphy-Beiner, Ashleigh
    Murphy, Roberta
    Martell, Jonny
    Blemings, Allan
    Erritzoe, David
    Nutt, David J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15) : 1402 - 1411
  • [10] BLIND MANS BLUFF - EFFECTIVENESS AND SIGNIFICANCE OF PSYCHOTHERAPY AND PHARMACOTHERAPY BLINDING PROCEDURES IN A CLINICAL-TRIAL
    CARROLL, KM
    ROUNSAVILLE, BJ
    NICH, C
    [J]. JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1994, 62 (02) : 276 - 280